Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Schizophrenia News

a caregiver speaks with a doctor
News
Caregivers Confirm Usability of Schizophrenia Cognition Rating Scale
11/14/2024
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving...
11/14/2024
Psych Congress Network
Conference presenter
News
Olanzapine/Samidorphan Demonstrates Favorable Safety Profile in 4-Year Open-Label Study
11/01/2024
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination...
11/01/2024
Psych Congress Network
dr and patient with brain model
News
Rehospitalization Risk, Treatment Costs Lower With Continued/Maintenance ECT
10/08/2024
Continuing electroconvulsive therapy (ECT) after an acute ECT series is linked with lower rehospitalization risk compared with not continuing ECT, according to study results published in JAMA Psychiatry.
Continuing electroconvulsive therapy (ECT) after an acute ECT series is linked with lower rehospitalization risk compared with not continuing ECT, according to study results published in JAMA Psychiatry.
Continuing electroconvulsive...
10/08/2024
Psych Congress Network

Advertisement

A midlife woman sits on a couch and looks out the window with her chin resting on her fist.
News
Menopausal Hormone Therapy Benefits Midlife Women With Schizophrenia
10/04/2024
Menopausal hormone therapy (MHT) is associated with a 16% lower risk of psychosis relapse in midlife women with schizophrenia or schizoaffective disorder (SSD).
Menopausal hormone therapy (MHT) is associated with a 16% lower risk of psychosis relapse in midlife women with schizophrenia or schizoaffective disorder (SSD).
Menopausal hormone therapy (MHT)...
10/04/2024
Psych Congress Network
FDA approval featuring craig chepke
News
FDA Approves First Schizophrenia Treatment in Over 3 Decades
09/27/2024
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
The US Food and Drug...
09/27/2024
Psych Congress Network
A human hand breaks off a head from a wooden figure against a light blue background
News
TBI Linked With Increased Schizophrenia Risk
08/20/2024
Traumatic brain injury (TBI) increases subsequent schizophrenia risk by 33%, according to study results published in Psychiatry Research.
Traumatic brain injury (TBI) increases subsequent schizophrenia risk by 33%, according to study results published in Psychiatry Research.
Traumatic brain injury (TBI)...
08/20/2024
Psych Congress Network

Advertisement

A brain puzzle against an orange background
News
Most Patients With Schizophrenia Relapse-Free With Paliperidone Palmitate, Open Label Extension Study Finds
08/01/2024
In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years.
In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years.
In a 2-year open-label extension...
08/01/2024
Psych Congress Network
News
Some Antipsychotics Linked To Elevated Pneumonia Risk
07/17/2024
Pneumonia in patients with schizophrenia is associated with the use of specific antipsychotics, according to study findings published in JAMA Psychiatry.
Pneumonia in patients with schizophrenia is associated with the use of specific antipsychotics, according to study findings published in JAMA Psychiatry.
Pneumonia in patients with...
07/17/2024
Psych Congress Network
a doctor writes notes
News
Subcutaneous Olanzapine Long-Acting Injection Meets Efficacy Endpoint in Phase 3 Trial
06/25/2024
An investigational, once-monthly, subcutaneous long-acting injection of olanzapine called TEV-‘749 met its primary endpoint in the efficacy portion of the phase 3 SOLARIS trial.
An investigational, once-monthly, subcutaneous long-acting injection of olanzapine called TEV-‘749 met its primary endpoint in the efficacy portion of the phase 3 SOLARIS trial.
An investigational,...
06/25/2024
Psych Congress Network

Advertisement

A doctor takes notes on paper on a clipboard sitting on a desk
News
Third Xanomeline-Trospium Trial Shows Improvement in Schizophrenia Symptoms
06/18/2024
Xanomeline-trospium chloride was efficacious and well-tolerated in adults with schizophrenia experiencing acute psychosis, according to trial results published in JAMA Psychiatry. “In the phase 3 EMERGENT-3 trial in people with...
Xanomeline-trospium chloride was efficacious and well-tolerated in adults with schizophrenia experiencing acute psychosis, according to trial results published in JAMA Psychiatry. “In the phase 3 EMERGENT-3 trial in people with...
Xanomeline-trospium chloride was...
06/18/2024
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use